0000000001169000
AUTHOR
S Malato
Cardiovascular events and intensity of treatment in polycythemia vera.
A b s t r ac t Background Current treatment recommendations for patients with polycythemia vera call for maintaining a hematocrit of less than 45%, but this therapeutic strategy has not been tested in a randomized clinical trial. Methods We randomly assigned 365 adults with JAK2-positive polycythemia vera who were being treated with phlebotomy, hydroxyurea, or both to receive either more intensive treatment (target hematocrit, <45%) (low-hematocrit group) or less intensive treatment (target hematocrit, 45 to 50%) (high-hematocrit group). The primary composite end point was the time until death from cardiovascular causes or major thrombotic events. The secondary end points were cardiovascula…
Preface
This Special Issue of Catalysis Today includes selected papers presented at the 5th European Conference on Solar Chemistry & Photocatalysis: Environmental Applications (SPEA 5). The conference, held from 4th to 8th October 2008, was organized by Leonardo Palmisano and Vincenzo Augugliaro in Palermo (Italy). The 252 delegates (representing 757 authors) who came from many different European and non-European countries delivered four plenary lectures and 49 oral presentations. To emphasise the poster presentation, the 184 posters were briefly introduced by the appropriate Session Chairman before each oral sessions began. Both oral and poster presentations were divided into the following five to…